| Name | Timberview Care Center |
|---|---|
| Location | 1023 6th Ave Sw, Albany, Oregon |
| Certified By | Medicare and Medicaid |
| No. of Certified Beds | 67 |
| Occupancy Rate | 85.22% |
| Medicare ID (CCN) | 385107 |
| Legal Business Name | Pci Care Venture I Inc. |
| Ownership Type | For Profit - Corporation |
| NPI Number | 1427044619 |
| Organization Name | PCI CARE VENTURE I, INC |
| Doing Business As | TIMBERVIEW CARE CENTER |
| Address | 1023 6th Ave Sw, Albany, OR 97321 |
| Phone Number | 541-926-8664 |
News Archive
A high sodium intake over a prolonged period of time is associated with increased vascular dysfunction, which may lead to hypertension, researchers report.
Provident Healthcare Ventures, LLC is pleased to announce the launch of its inaugural Principals Fund I with $25 million of committed capital. All capital invested in the Fund will be provided by the principals of Provident, affirming their belief that providing early-stage healthcare services companies with crucial resources, such as capital and operating expertise, will significantly increase enterprise value over the life of the investment.
Researchers at Yale School of Medicine have made major discoveries that could lead to new treatments for lung disorders in premature babies. In a mouse study, the team located key molecules that switch on stress pathways in preterm lung disorders, and also found that when parts of these pathways were blocked with a pain drug, lung damage was prevented or reversed.
Hospital readmissions are miserable for patients, and a huge cost - more than $17 billion a year in avoidable Medicare bills alone - for a nation struggling with the price of health care. Now, with Medicare fining facilities that don't reduce readmissions enough, the nation is at a crossroads as hospitals begin to take action.
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
› Verified 1 days ago
| Ratings from Surveys (Inspections): | |
| Ratings from Quality Measures: | |
| Ratings from Staffing Data: | |
| Overall Rating: |
|---|
News Archive
A high sodium intake over a prolonged period of time is associated with increased vascular dysfunction, which may lead to hypertension, researchers report.
Provident Healthcare Ventures, LLC is pleased to announce the launch of its inaugural Principals Fund I with $25 million of committed capital. All capital invested in the Fund will be provided by the principals of Provident, affirming their belief that providing early-stage healthcare services companies with crucial resources, such as capital and operating expertise, will significantly increase enterprise value over the life of the investment.
Researchers at Yale School of Medicine have made major discoveries that could lead to new treatments for lung disorders in premature babies. In a mouse study, the team located key molecules that switch on stress pathways in preterm lung disorders, and also found that when parts of these pathways were blocked with a pain drug, lung damage was prevented or reversed.
Hospital readmissions are miserable for patients, and a huge cost - more than $17 billion a year in avoidable Medicare bills alone - for a nation struggling with the price of health care. Now, with Medicare fining facilities that don't reduce readmissions enough, the nation is at a crossroads as hospitals begin to take action.
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
› Verified 1 days ago
| Number of Facility Reported Incidents | 0 |
| Number of Substantiated Complaints | 0 |
| Number of Fines | 0 |
| Total Amount of Fines in Dollars | $0 |
| Number of Payment Denials | 0 |
| Total Number of Penalties | 0 |
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Percentage of long-stay residents whose need for help with daily activities has increased | 7.19 | 14.46 |
| Percentage of long-stay residents who lose too much weight | 20.29 | 5.51 |
| Percentage of low risk long-stay residents who lose control of their bowels or bladder | 72.46 | 48.41 |
| Percentage of long-stay residents with a catheter inserted and left in their bladder | 5.66 | 1.79 |
| Percentage of long-stay residents with a urinary tract infection | 1.96 | 2.65 |
| Percentage of long-stay residents who have depressive symptoms | 8.78 | 5.05 |
| Percentage of long-stay residents who were physically restrained | 0 | 0.23 |
| Percentage of long-stay residents experiencing one or more falls with major injury | 1.29 | 3.36 |
| Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine | 98.71 | 93.87 |
| Percentage of long-stay residents who received an antipsychotic medication | 24.52 | 14.2 |
| Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine | 84.54 | 83.88 |
| Percentage of short-stay residents who newly received an antipsychotic medication | 1.52 | 1.79 |
| Percentage of long-stay residents whose ability to move independently worsened | 21.36 | 17.09 |
| Percentage of long-stay residents who received an antianxiety or hypnotic medication | 11.43 | 19.7 |
| Percentage of high risk long-stay residents with pressure ulcers | 4.2 | 7.32 |
| Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine | 98.22 | 95.98 |
| Percentage of short-stay residents who made improvements in function | 78.32 | 67.99 |
| Percentage of short-stay residents who were assessed and appropriately given the seasonal influenza vaccine | 79.26 | 82.93 |
News Archive
A high sodium intake over a prolonged period of time is associated with increased vascular dysfunction, which may lead to hypertension, researchers report.
Provident Healthcare Ventures, LLC is pleased to announce the launch of its inaugural Principals Fund I with $25 million of committed capital. All capital invested in the Fund will be provided by the principals of Provident, affirming their belief that providing early-stage healthcare services companies with crucial resources, such as capital and operating expertise, will significantly increase enterprise value over the life of the investment.
Researchers at Yale School of Medicine have made major discoveries that could lead to new treatments for lung disorders in premature babies. In a mouse study, the team located key molecules that switch on stress pathways in preterm lung disorders, and also found that when parts of these pathways were blocked with a pain drug, lung damage was prevented or reversed.
Hospital readmissions are miserable for patients, and a huge cost - more than $17 billion a year in avoidable Medicare bills alone - for a nation struggling with the price of health care. Now, with Medicare fining facilities that don't reduce readmissions enough, the nation is at a crossroads as hospitals begin to take action.
Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of TCR engineered T-cell therapy to treat cancer, today announced a poster presentation of data on its lead clinical program, an affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen, in both solid and hematologic cancers.
› Verified 1 days ago